bluebird bio Appoints Chip Baird as Chief Financial Officer

  • CFO with proven track record will help lead transition to commercial
    company
  • Jeff Walsh to assume role of chief strategy officer
  • Jason Cole to assume role of chief operating and legal officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird
bio, Inc
. (Nasdaq:BLUE) announced Chip Baird will join the company
effective today and assume the role of chief financial officer (CFO).
Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was
the CFO for the past seven years and brings a demonstrated track record
of successfully leading companies in all phases of discovery,
development and commercialization. Jeff Walsh, who has held various
roles over the last eight years at bluebird bio — including chief
operating officer and, most recently, chief financial and strategy
officer — will assume the new dedicated role of chief strategy officer
to drive corporate development and the company’s overall growth
strategy. In addition, Jason Cole, who has served as general counsel
since 2014 and chief legal officer since 2016, will assume the new and
expanded role of chief operating and legal officer overseeing both
operations and legal functions for the company.

Chip’s deep knowledge of our industry and expertise in managing
financial and capital strategies are a strong addition to bluebird as we
prepare for commercialization and the potential European launch of our
first product in 2019,” said Nick Leschly, chief bluebird. “I’m excited
to welcome Chip to bluebird, as he shares our commitment to patients,
our people and our culture. His experience in U.S. and EU rare disease
product launches, as well as in expansion of business operations into
global markets, will be instrumental as we evolve to a
multiproduct, global company over the next several years.”

I am excited to join bluebird at such an important time in the
company’s history with multiple potential product approvals on the
horizon. The patient-focused mission, the extraordinary science and the
bluebird culture made this a compelling opportunity,” said Mr. Baird. “I
look forward to working with the team in a global commercial setting
while continuing to invest in the science and the pipeline to deliver
gene therapy to patients.”

Mr. Leschly added, “I want to thank Jeff for the strong foundation and
financial position he’s put in place as our CFO, and I look forward to
his continued partnership on advancing our growth strategies to ensure
our existing and future potential products find their way to clinicians
and patients globally. In addition, Jason’s leadership and track record
of delivering results across many areas of our business make him ideally
suited for a broader role inclusive of operations to help us scale
across multiple product platforms and geographies.”

Chip Baird Biography

William D. “Chip” Baird has more than 20 years of financial and
strategic planning experience in the biopharmaceutical sector. For the
past seven years, Mr. Baird served as CFO of Amicus Therapeutics, Inc.
During his tenure, Amicus transformed from a U.S.-based, single-product
research and development (R&D) company to a global commercial company
with a robust clinical pipeline. Prior to Amicus, Mr. Baird spent 10
years as CFO of PTC Therapeutics with responsibility for all areas of
finance, investor and public relations, human resources, facilities and
project management. During his tenure at Amicus and PTC, Mr. Baird
secured more than $1.9 billion in growth capital through a variety of
equity and debt instruments in the public and private markets as well as
significant funding from collaborations with industry-leading
pharmaceutical and biotech companies. Previously, Mr. Baird worked in
the life science practice at L.E.K. Consulting, a strategy consulting
firm, and began his career at First Union National Bank in corporate
debt underwriting.

Mr. Baird currently serves as a director of Axcella Health. He received
a BS from Georgetown University’s Edmund A. Walsh School of Foreign
Service and an MBA in finance from The Wharton School at the University
of Pennsylvania.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our
Cambridge, Mass., headquarters, we’re developing gene therapies for
severe genetic diseases and cancer, with the goal that people facing
potentially fatal conditions with limited treatment options can live
their lives fully. Beyond our labs, we’re working to positively disrupt
the healthcare system to create access, transparency and education so
that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting
our care and expertise to work across a spectrum of disorders by
researching cerebral adrenoleukodystrophy, sickle cell disease,
transfusion-dependent β-thalassemia and multiple myeloma using three
gene therapy technologies: gene addition, cell therapy and
(megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and
Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio,
LinkedIn,
Instagram
and YouTube.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that the preliminary positive efficacy and safety results
from our prior and ongoing clinical trials of our product candidates
will not continue or be repeated in our ongoing or planned clinical
trials; risks that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory submissions
or to support marketing approval in the U.S. and EU; and the risk that
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent Form 10-Q as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and bluebird bio undertakes no duty to update this
information unless required by law.

Contacts

Investors & Media
Investors:
Elizabeth Pingpank,
617-914-8736
epingpank@bluebirdbio.com

Media:
Stephanie Fagan, 201-572-9581
sfagan@bluebirdbio.com

error: Content is protected !!